马拉维布兰太尔乙型肝炎疫苗接种影响及抗病毒治疗未满足需求
2016至2018年在马拉维布兰太尔开展家庭调查,从97386名普查对象中随机抽样6073人,估计成人HBsAg血清流行率为5.1%,疫苗引入后出生儿童为0.3%,估计疫苗影响为95.8%。HBsAg阳性成人中26%为HIV阳性,HIV阴性者按WHO、欧洲和美国肝病学会标准符合抗病毒治疗比例分别为3%、6%和9%。
要点
- 婴儿乙肝疫苗接种估计影响达95.8%,引入后出生儿童HBsAg流行率降至0.3%。
- 成人HBsAg血清流行率为5.1%,HBsAg阳性成人中26%为HIV阳性。
- HIV阴性HBsAg阳性成人符合抗病毒治疗比例按WHO、欧洲、美国标准分别为3%、6%、9%。
核心结论
- 婴儿乙肝疫苗接种在降低马拉维城市地区HBsAg流行率方面高度有效。
- 高达9%的HBsAg阳性HIV阴性成人符合抗病毒治疗条件但存在未满足的治疗需求。
研究设计与样本
- 2016至2018年在马拉维布兰太尔开展家庭研究,从普查人群中随机抽样。
- 共普查97386人,抽样6073人,中位年龄18岁,女性占56.7%。
- 通过比较疫苗实施前后出生个体,采用二项对数线性回归估计婴儿乙肝疫苗接种影响。
- 在HBsAg阳性成人中评估抗病毒治疗资格。
主要发现
- 成人HBsAg血清流行率为5.1%(95% CI 4.3%-6.1%),疫苗引入后出生儿童为0.3%(95% CI 0.1%-0.6%)。
- 估计疫苗影响为95.8%(95% CI 70.3%-99.4%)。
- HBsAg阳性成人中26%为HIV阳性。
- HIV阴性个体中,按WHO、欧洲和美国肝病学会标准符合乙肝治疗资格的比例分别为3%、6%和9%。
关键数值与推荐
- WHO标准:HIV阴性HBsAg阳性成人中3%符合乙肝治疗资格。
- 欧洲肝病学会标准:HIV阴性HBsAg阳性成人中6%符合乙肝治疗资格。
- 美国肝病学会标准:HIV阴性HBsAg阳性成人中9%符合乙肝治疗资格。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B is the leading cause of cirrhosis and liver cancer in sub-Saharan Africa. To reduce mortality, antiviral treatment programs are needed. We estimated prevalence, vaccine impact, and need for antiviral treatment in Blantyre, Malawi. METHODS: We conducted a household study in 2016-2018. We selected individuals from a census using random sampling and estimated age-sex-standardized hepatitis B surface antigen (HBsAg) seroprevalence. Impact of infant hepatitis B vaccination was estimated by binomial log-linear regression comparing individuals born before and after vaccine implementation. In HBsAg-positive adults, eligibility for antiviral therapy was assessed. RESULTS: Of 97386 censused individuals, 6073 (median age 18 years; 56.7% female) were sampled. HBsAg seroprevalence was 5.1% (95% confidence interval [CI], 4.3%-6.1%) among adults and 0.3% (95% CI, .1%-.6%) among children born after vaccine introduction. Estimated vaccine impact was 95.8% (95% CI, 70.3%-99.4%). Of HBsAg-positive adults, 26% were HIV-positive. Among HIV-negative individuals, 3%, 6%, and 9% were eligible for hepatitis B treatment by WHO, European, and American hepatology association criteria, respectively. CONCLUSIONS: Infant HBV vaccination has been highly effective in reducing HBsAg prevalence in urban Malawi. Up to 9% of HBsAg-positive HIV-negative adults are eligible, but have an unmet need, for antiviral therapy.
引用
- Stockdale AJ, Meiring JE, Shawa IT, et al. Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi. J Infect Dis. 2022. PMID: 34752631. doi:10.1093/infdis/jiab562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。